Who Owns Lung Nodule Follow Up in Health Systems and Why That Matters

Lung nodules are detected every day across U.S. health systems. What remains unclear in many organizations is who owns what happens next.

Radiologists identify nodules. Primary care physicians receive reports. Pulmonologists manage high-risk cases. Nurse navigators coordinate follow up. Administrators oversee quality metrics. Yet when follow up fails, responsibility is often diffuse.

This lack of ownership is one of the most common reasons lung nodules do not receive timely follow up. For radiology leaders, IPN program leads, and hospital executives, clarifying ownership is not an operational detail. It is a patient safety issue.

Incidental pulmonary nodules are common. Studies estimate that up to 30 percent of chest CT scans identify at least one pulmonary nodule. With more than 90 million CT scans performed annually in the United States, this translates to well over a million new nodules each year.

Despite clear clinical guidelines, follow up remains inconsistent. Multiple studies have shown that 30 to 50 percent of patients with incidentally detected lung nodules do not receive guideline-recommended follow up imaging. In some systems, the rate is higher when nodules are detected outside formal lung cancer screening programs.

Missed follow up has real consequences. Research has shown that nodules lost to follow up are associated with delayed lung cancer diagnosis, more advanced stage at diagnosis, and worse survival outcomes.

The question health systems must ask is not whether nodules are being detected. It is whether someone is clearly accountable for ensuring follow up occurs.

Ownership of lung nodule follow up often fails because responsibility is spread across multiple roles without a defined handoff.

Radiologists detect nodules and document them in reports. Their primary responsibility ends with accurate interpretation and communication of findings. In many organizations, radiologists are not expected to track patients longitudinally.

Primary care physicians receive the report but may not see it in a timely manner. They manage many competing priorities and may not be aware of guideline-specific follow up recommendations for nodules.

Pulmonologists typically become involved only after referral. If a referral is not generated, the patient may never reach specialty care.

Nurse navigators are often tasked with coordinating follow up, but they are rarely empowered with formal ownership. In many health systems, navigators operate without dedicated infrastructure or authority.

Hospital leadership may assume that existing processes are sufficient, particularly if no adverse events have surfaced recently.

The result is a system where everyone is involved, but no one clearly owns the outcome.

From a radiology standpoint, the problem is not detection. It is transition.

Radiology reports often include descriptive findings but lack standardized follow up recommendations. Studies have found that fewer than half of radiology reports include explicit follow up guidance for pulmonary nodules.

Even when recommendations are included, they may not be clearly actionable. Free text reporting can obscure key details such as nodule size, risk category, and suggested interval.

Radiologists are increasingly aware that detection without follow up creates downstream risk. However, radiology departments alone cannot own longitudinal care.

What radiology can own is consistency. Structured reporting, standardized language, and clear identification of actionable nodules reduce ambiguity. Radiology also plays a critical role in enabling IPN programs by ensuring nodules are reliably flagged.

Ownership begins with clarity. Radiology sets the foundation, but it cannot carry follow up alone.

Incidental Pulmonary Nodule programs exist to solve the ownership gap. When designed well, an IPN program creates a single point of accountability for nodule follow up.

Successful IPN programs share common features:

Published case studies from large U.S. health systems show that IPN programs can significantly improve follow up adherence and reduce diagnostic delays. Programs that assign clear ownership report higher completion rates of recommended imaging and earlier stage lung cancer diagnoses.

However, IPN programs fail when ownership is nominal rather than real. Program leads must have authority to act. This includes the ability to contact patients, order follow up imaging under protocol, and escalate cases when delays occur.

Without this authority, IPN programs become passive registries rather than active safety nets.

For hospital executives, lung nodule follow up is often invisible until something goes wrong.

Missed nodules rarely trigger immediate financial penalties. They surface later as advanced cancers, malpractice claims, or quality reviews. By then, root cause analysis often reveals fragmented responsibility.

From a governance perspective, ownership of lung nodule follow up should be treated like other patient safety processes. Just as hospitals define ownership for abnormal lab results or critical findings, they must define ownership for nodules.

This involves explicit decisions:

Health systems that have addressed this proactively report improved audit readiness and reduced risk exposure. Leadership support is consistently cited as a key factor in IPN program success.

Ownership is not about adding bureaucracy. It is about preventing avoidable harm.

Some organizations attempt shared ownership models, where radiology, primary care, and pulmonology each carry partial responsibility. In practice, this often fails.

Shared ownership without clear accountability leads to diffusion of responsibility. Each team assumes someone else is managing follow up.

Research on diagnostic safety consistently shows that ambiguous responsibility is a major contributor to missed diagnoses. Lung nodules are a textbook example.

Clear ownership does not exclude collaboration. It simply defines who is responsible for ensuring the process completes.

Technology alone cannot solve the ownership problem. However, it can support accountable workflows.

Tools that reliably identify nodules, standardize measurements, and provide longitudinal visibility enable IPN programs to function at scale. They reduce dependence on manual review and improve consistency.

Qure.ai provides FDA-cleared AI tools that support this foundation.

These tools do not assign ownership. They support teams that have already made an ownership decision. By improving detection consistency and measurement reliability, they enable IPN programs and radiology teams to work from objective data.

For CXOs, this distinction matters. Technology should reinforce governance decisions, not substitute for them.

Health systems that successfully manage lung nodules typically answer three questions clearly:

The most effective models place ownership within a formal IPN program, supported by radiology and pulmonary services, with executive oversight.

Nurse navigators often execute the work, but ownership must sit at the program level, not with individuals.

Clear ownership improves outcomes in measurable ways.

It reduces missed follow ups by ensuring no nodule is left unmanaged. It shortens time to diagnosis by preventing delays. It improves patient trust by providing clear communication and continuity.

From a system perspective, it reduces risk. Health systems with formal IPN programs report better documentation, improved compliance with guidelines, and fewer adverse events related to delayed diagnosis.

For radiology leaders, it ensures that findings lead to action. For IPN leads, it provides authority to manage care. For CXOs, it aligns patient safety with operational accountability.

Lung nodules will continue to increase as imaging volumes grow. Detection will improve. Without ownership, follow up will continue to fail.

The question is not whether health systems can afford to define ownership. It is whether they can afford not to.

Clear ownership of lung nodule follow up is a foundational step toward reliable early lung cancer diagnosis.

To learn more about FDA-cleared tools that support lung nodule detection and longitudinal assessment within IPN and radiology workflows, download the Qure.ai product brochure.